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http://www.biomedcentral.com/1471-2407/13/420RESEARCH ARTICLE Open AccessAssociation of thiazolidinediones with gastric
cancer in type 2 diabetes mellitus:
a population-based case–control study
Shen-Shong Chang1,2,3 and Hsiao-Yun Hu4,5*Abstract
Background: It has been shown that peroxisome proliferator-activated receptors (PPAR) have physiological and
pharmacological ligands. The objective is to assess the association between thiazolidinediones (TZDs) and the
occurrence of gastric cancer.
Methods: We conducted a population-based nested case–control study. Data were retrospectively collected from
the National Health Insurance Research Database (NHIRD). The cases consisted of all diabetes mellitus (DM) patients
aged 30 to 99 years, and who had a first time diagnosis of gastric cancer in the study cohort. The controls were
matched to cases by age, sex, and index date. The adjusted odds ratio (OR) and 95% confidence interval (CI) were
estimated by using multiple logistic regression.
Results: Records from 357 gastric cancer and 1,428 selected matched controls were included in the analyses of
gastric cancer risk. A total of 7% or 9.5% of the cases and 10.8% or 14.8% of the controls had used any quantity of
at least 2 prescriptions for pioglitazone or rosiglitazone, respectively. After adjusting for possible confounders,
pioglitazone (OR = 0.93, P > 0.05) and rosiglitazone (OR = 1.21, P > 0.05), had no significant association of decreasing
gastric cancer. After adjusting for possible confounders, pioglitazone (OR = 0.70, P > 0.05) or rosiglitazone (OR = 0.79,
P > 0.05), had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 260
defined daily doses (DDDs), respectively. Moreover, adjusting for possible confounders pioglitazone (OR = 0.68,
P > 0.05) or rosiglitazone (OR = 0.74, P > 0.05) had no significant trend toward decreasing gastric cancer risk with
increasing cumulative doses ≥ 1 year, respectively.
Conclusions: Our results did not show evidence to support that TZD derivatives in DM patients reduces gastric
cancer occurrence.
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mellitusBackground
Gastric carcinoma is the second most common cancer
in the world [1]. The diagnosis of cancer and diabetes in
the same people occurs more frequently [2]. Numerous
factors may affect the positive association between dia-
betes and cancer. Potential risk factors common to both
diseases include age, sex, physical activity, obesity, diet,
alcohol, and smoking [3-6]. Numerous studies have been* Correspondence: hyhu@ym.edu.tw
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reproduction in any medium, provided the orperformed to research therapeutic targets and drugs cap-
able of preventing and treating gastric carcinoma and
other malignancies. Evidence from observational studies
shows that oral hypoglycemic agents are associated with
either an increased or reduced risk of cancer [7].
Peroxisome proliferator-activated receptors (PPARs)
indicate a family of nuclear receptors that are related to
thyroid hormones, insulin sensitivity, adipocyte differen-
tiation, and retinoid receptors [8,9]. Three PPAR sub-
types, PPAR-α、β、γ have been indentified. It has been
shown that PPAR-γ has physiological and pharmaco-
logical ligands [9]. Anti-diabetic thiazolidinedionesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to synthetic PPAR-γ, which can decrease insulin resist-
ance in peripheral tissues and hepatocytes, and increase
the action of insulin hormones [10]. PPAR-γ is impli-
cated as a putative therapeutic target for cancer in a var-
iety of tumors as several observations have suggested
that stimulation of PPAR-γ function may inhibit carcino-
genesis and tumor cell growth [11,12]. Ligands of PPAR-
γ have been demonstrated to suppress the propagation
of these cancers in vitro [13-16]. One well-known
category of ligands is the TZDs, which include
rosiglitazone and 15-deoxy-prostaglandin-J2 (15d-PGJ(2))
[17]. Lu et al. [18] has previously reported that troglitazone
suppresses stomach cancer through the activation of
PPAR-γ. It had been reported that stomach cancer is
suppressed by PPAR-γ-ligand-mediated apoptosis [19].
Konturek et al. [20] has recently shown that PPAR-γ is
implicated in Helicobacter pylori (H. pylori)-related gas-
tric carcinogenesis, and that a PPAR-γ agonist may have
potential in a therapeutic cancer role. In contrast to the
link between the PPAR-γ ligand and gastric carcinoma
in vitro study, results of other clinical studies remain
unknown.
No large clinical trial or nationally representative ob-
servational study has been conducted to address this
issue. Thus, we conducted a nested case–control study
based on the National Health Insurance Research Data-
base (NHIRD) in Taiwan. The main outcome of interest
is to assess the association between TZDs (pioglitazone
and rosiglitazone) and the occurrence of gastric cancer.
Methods
Data source
This nationwide cohort study was based on patient data
obtained from the National Health Insurance Database
(NHID), which is managed by the Taiwan National Health
Research Institute (NHRI). The NHID contains health care
data for 99% of the population of Taiwan (approximately
23 million people). The NHI sample files, which are
established and managed by the NHRI, consist of compre-
hensive use and enrollment information for a randomly se-
lected sample of 1,000,000 NHI beneficiaries, representing
approximately 5% of all enrollees in Taiwan in 2000. The
NHRI is the only institute that is approved to conduct
samplings of a representative portion of the entire popula-
tion. Although privacy protections are maintained, the re-
imbursement data for sampled patients were retrieved and
used for academic research after obtaining approval. The
NHID contains comprehensive information, including
demographic data, dates of clinical visits, diagnostic codes,
and details of prescriptions. The International Classifica-
tions of Diseases, Revision 9, Clinical Modification (ICD-
9-CM) was used to define diseases during the period of this
study. This study has been approved by the NHRI.Study design
A nested case–control approach is a useful alternative to
cohort analysis to study time-dependent exposure [21].
The risk estimates from cohort and nested case–control
analysis should be similar if confounding factors are
controlled in both analyses. The strength of the nested
case–control study design may be particularly useful in
rare cases [22].
Study patients
Diabetes mellitus (DM) patients were identified using in-
patient discharge records, or by 3 or more ambulatory
care claims with a diagnosis of ICD-9-CM: 250. From
the NHID, patients who had DM, and were using
pioglitazone and rosiglitazone between January 1, 2000
and December 31, 2010 were compared to DM patients
who were not treated with pioglitazone or rosiglitazone.
Patients who had ever received a gastrectomy or vagot-
omy were excluded from the analyses. Patients with a
previous diagnosis of gastric cancer or Zollinger–Ellison
syndrome, and those who were less than 30 years old
and more than 99 years old were also excluded. We fur-
ther excluded those who had a hospital admission with
a discharge diagnosis of insulin-dependent diabetes
mellitus (ICD-9-CM 250.x1, 250.x3) or received a cata-
strophic illness certificate issued by the Department of
Health for Type 1 Diabetes.
Exposure to pioglitazone or rosiglitazone
Information on all TZDs prescription was extracted from
the NHRI prescription database. The defined daily dose
(DDD) is the assumed average maintenance dose per day
for drugs administered to adults and used according to
their main indications. The DDDs recommended by the
World Health Organization (WHO) [23] were used to
quantify the use of TZDs. Cumulative DDD was estimated
as the sum of dispensed DDDs of any TZDs (pioglitazone
or rosiglitazone) from January 1, 2000 to the index date.
The gathered data comprised the date of prescription,
daily dosage, and the number of days of drug supply. The
main exposure of interest was the use of pioglitazone or
rosiglitazone, which entered Taiwan’s market in June 2001
and March 2000, respectively.
Definition of gastric cancer
All patients aged 30–99 years in the study cohort, with
the first occurrence of stomach cancer ICD-9-CM
150.0-150.9 during the 11-year period, were included as
cases based on inpatient discharge records. Patients with
a previous diagnosis of gastric cancer were excluded. A
diagnosis of gastric cancer in the NHID required histo-
logic confirmation to be reported to the registry of the
Catastrophic Illness Patient Database. All potential cases
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Registry.Definition of control group
A risk-set sample (control sample from those in the ori-
ginal study cohort who remained free of outcome at the
time when a case occurred) matched by age (within
5 years), sex, and the number of days of follow-up, was
used as controls for the cohort. For newly diagnosed Type
2 Diabetes patients, case and controls were also matched
based on antidiabetic treatment duration (within 30 days)
at cancer diagnosis. For newly diagnosed diabetic patients,
the scheme that matched follow-up duration also consid-
ered diabetic duration. For prevalent patients with un-
known duration, we selected controls with the same
follow-up duration to reduce the confounding effect of
diabetes duration. Up to four controls were selected for
each patient [24].Definition of peptic ulcer history and ulcer bleeding
history
All endoscopically-diagnosed peptic ulcers in DM pa-
tients prior to the date of gastric cancer diagnosis,
according to ambulatory care and inpatient discharge re-
cords, were used for peptic ulcer history. Peptic ulcers
were defined as gastric ulcers (ICD-9-CM 531), duo-
denal ulcers (ICD-9-CM 532), and nonspecific peptic ul-
cers (ICD-9-CM 533) following endoscopic confirmation
from January 1, 2000 to the index date. Based on in-
patient discharge records prior to the date of gastric
cancer diagnosis, peptic ulcer bleeding (following endo-
scopic confirmation) was used as ulcer bleeding history.
Peptic ulcer bleeding was defined using ICD-9-CM
codes 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4,
532.6, 533.0 533.2, 533.4 and 533.6 following endoscopic
confirmation from January 1, 2000 to the index date.Definition H. pylori eradication rate
Patients placed into the category of H. pylori eradication
therapy were defined as those who received triple or quad-
ruple therapy during the same inpatient discharge record
or outpatient visit from January 1, 2000 to the index date.
The duration of therapy was between 7 and 14 days. H.
pylori infection is treated with multidrug regimen that
consists of proton pump inhibitors (PPIs) or histamine
receptor-2 blockers (H2-blockers), clarithromycin or tetra-
cycline, amoxicillin or metronidazole, and potentially
bismuth. The PPIs administered to patients that were
evaluated in this study were lansoprazole, esomeprazole,
omeprazole, pantoprazole, and rabeprazole and the H2-
blockers were cimetidine, famotidine, nizatidine, raniti-
dine, and roxatidine [25].Definition of comorbidities
Patient comorbidities were identified using inpatient dis-
charge records or by 3 or more ambulatory care claims with
the diagnosis of coronary artery disease (CAD): ICD-9-CM
410–414, cerebral vascular disease (CVD): ICD-9-CM 430–
438, chronic liver disease (CLD): 070.2x, 070.3x, V02.61,
070.41, 070.44, 070.51, 070.54, V02.62, 571.4, 571.2, 571.5,
571.6, 571.0x, 571.1x, 571.2, and 571.3x, chronic obstructive
pulmonary disease (COPD): ICD-9-CM 490–492, 494,
and 496, chronic kidney disease (CKD): ICD-9-CM
580–589, 250.4, 274.1, 283.11, 403.x1, 404.x2, 404.x3,
440.1, 442.1, 447.3, 572.4, 642.1x, 646.2x, and 794.4,
and gastroesophageal reflux disease (GERD): 530.81 or
erosive esophagitis (EE): 530.11.
Use of medication
Patients were categorized by their use of metformin, sulfo-
nylurea, glucosidase inhibitors, meglitinides, dipeptidyl
peptidase 4 (DPP-4) inhibitors, insulin, statins, angiotensin
receptor blockers (ARBs), angiotensin-converting en-
zyme (ACE) inhibitors, aspirin, cyclooxygenase-2 (COX-2)-
specific inhibitors, and non-steroidal anti-inflammatory
drugs (NSAIDs) with at least 2 prescription prior to the
index date of gastric cancer diagnosis [26].
Statistical analysis
For comparisons of proportions, χ2 statistics were used. A
conditional logistic regression model was used to estimate
the relative magnitude in relation to the use of TZDs. Ex-
posure was defined as patients who received at least 2 pre-
scriptions for a TZD at any time between January 1, 2000
and the index date [26]. In the analysis, the participants
were categorized into one of 2 TZDs exposure categories:
nonuse, past use, and recent use. Furthermore, we divided
the person-time-product into recent use (including
current medication and discontinuation of medication
prior to gastric cancer diagnosis < 6 months), past use (drug
discontinuation to gastric cancer diagnosis ≥ 6 months),
and non-use. The participants were categorized into
users of dosages less than the median (< 260 DDDs)
and users of dosages equal or greater than the median
(≥ 260 DDDs). In the dose- and duration- response
analysis, we calculated the odds ratios (OR) for higher
(≥ 260 DDDs) or lower (< 260 DDDs), and for cumulative
treatment duration ≥ 1 year or < 1 year. The OR and their
95% confidence intervals (CI) were calculated using pa-
tients with no exposure as the reference. All statistical
analyses implemented in the present study were
performed using an SAS statistical package (SAS System
for Windows, version 9.2; SAS Institute, Cary, NC, USA).
Results
Records from 357 gastric cancer and 1,428 selected
matched controls were included in the analyses of
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demographic characteristics, such as age, sex, peptic
ulcer history, ulcer bleeding history, H. pylori eradication
rate, comorbidities, and medication of gastric cancer
cases and controls. The patients had significantly higher
rates of peptic ulcer history and ulcer bleeding history.Table 1 Characteristics, comorbidities, and medication
use among cases and controls
Variables Cases Controls P value
N = 357 % N = 1,428 %
Age at DM 0.483
30-60 69 15.90 300 17.28
≥60 288 66.36 1,128 64.98
Sex 1.000
Male 215 49.54 568 32.72
Female 142 32.72 860 49.54
Peptic ulcer history 172 39.63 334 19.24 <0.001
Ulcer bleeding history 61 14.06 156 8.99 <0.001
HP eradication rate 33 7.60 139 8.01 0.779
Comorbidities
CAD 120 27.65 603 34.74 0.003
CVD 84 19.35 466 26.84 <0.001
CLD 78 17.97 337 19.41 0.484
COPD 98 22.58 465 26.79 0.063
CKD 77 17.74 431 24.83 0.001
GERD or EE 21 4.84 91 5.24 0.733
Medications
Pioglitazone 25 5.76 154 8.87 0.033
Rosiglitazone 34 7.83 211 12.15 0.010
Metformin 236 54.38 990 57.03 0.241
Sulfonylurea 256 58.99 1,022 58.87 0.958
Glucosidase inhibitors 36 8.29 293 16.88 <0.001
Meglitinides (Glinides) 35 8.06 241 13.88 <0.001
DPP-4 inhibitors 1 0.23 85 4.90 <0.001
Insulin 37 8.53 265 15.26 <0.001
Statins 86 19.82 531 30.59 <0.001
ARBs 88 20.28 534 30.76 <0.001
ACE inhibitors 126 29.03 560 32.26 0.173
Aspirin 118 27.19 610 35.14 <0.001
COX-2 inhibitors 27 6.22 189 10.89 0.003
NSAIDs 74 17.05 432 24.88 <0.001
DM diabetes mellitus, HP Helicobacter pylori, CAD coronary artery disease, CVD
cerebral vascular disease, CLD chronic liver disease, COPD chronic obstructive
pulmonary disease, CKD chronic kidney disease, GERD gastroesophageal reflux
disease, EE erosive esophagitis, DPP-4 inhibitors dipeptidyl peptidase 4
inhibitors, ARBs angiotensin receptor blockers, ACE inhibitors angiotensin-
converting enzyme inhibitors, COX-2 inhibitors cyclooxygenase-2 specific
inhibitors, NSAIDs non-steroidal anti-inflammatory drugs. N number.No significant difference between the patients and the
controls was found for the H. pylori eradication rate.
The relationship between the use of TZDs and gastric
cancer is shown in Tables 2 and 3. A total of 7% of the
patients and 10.8% of the controls had used at least 2
prescriptions for pioglitazone, as shown in Table 2. Any-
use of pioglitazone (OR = 0.62, P < 0.05) was associated
with a decreased crude OR for gastric cancer. However,
after adjusting for possible confounders (including age,
sex, peptic ulcer history, ulcer bleeding history, H. pylori
eradication rate, comorbidities, and medication), any-use
of pioglitazone (OR = 0.93, P > 0.05) had no significant
association with decreasing gastric cancer. When
pioglitazone use was categorized by cumulative dosage,
the crude OR was 0.77 (P > 0.05) for the group with
cumulative pioglitazone use < 260 DDDs, and was 0.49
(P < 0.05) for the group with cumulative pioglitazone
use ≥ 260 DDDs, compared with non-use. After adjusting
for possible confounders, no significant trend was ob-
served toward decreasing gastric cancer risk with increas-
ing cumulative doses ≥ 260 DDDs (OR = 0.70, P > 0.05).
When pioglitazone use was categorized by cumulative
duration, the crude OR was 0.73 (P > 0.05) for the
group with cumulative pioglitazone use < 1 year, and
was 0.47 (P < 0.05) for the group with cumulative
pioglitazone use ≥1 year, compared with non-use. After
adjusting for possible confounders, no significant trend
was observed toward decreasing gastric cancer risk with in-
creasing cumulative duration ≥1 year (OR = 0.68, P > 0.05),
as shown in Table 2.
A total of 9.5% of the patients and 14.8% of the controls
had used some quantity of at least 2 prescriptions for
rosiglitazone, as shown in Table 3. Any-use of
rosiglitazone (OR = 0.61, P < 0.05) was associated with a
decreased crude OR for gastric cancer. After adjusting for
possible confounders, any-use of rosiglitazone (OR = 1.21,
P > 0.05) had no significant association with decreasing
gastric cancer. When rosiglitazone use was categorized by
cumulative dosage, the crude OR was 0.92 (P > 0.05) for
the group with cumulative rosiglitazone use < 260 DDDs,
and was 0.35 (P < 0.05) for the group with cumulative
rosiglitazone use ≥ 260 DDDs, as compared with non-use.
After adjusting for possible confounders, no significant
trend was observed toward decreasing gastric cancer risk
with increasing cumulative doses ≥ 260 DDDs (OR = 0.79,
P > 0.05). When rosiglitazone use was categorized by cu-
mulative duration, the crude OR was 0.85 (P > 0.05) for
the group with cumulative rosiglitazone use < 1 year,
and was 0.32 (P < 0.05) for the group with cumulative
rosiglitazone use ≥ 1 year compared with non-use.
After adjusting for possible confounders no significant
trend toward decreasing gastric cancer risk was noted
with increasing cumulative duration ≥ 1 year (OR = 0.74,
P > 0.05), as shown in Table 3.
Table 2 Associations between pioglitazone use and gastric cancer risk in a population-based nested case–control study
Variables Pioglitazone
Cases Controls Crude OR †Adjusted OR ‡Adjusted OR
N = 357 % N = 1,428 %
Nonuse 332 93.0 1,274 89.2 1.00 1.00 1.00
Any use 25 7.0 154 10.8 0.62* 0.65* 0.93
Recent use 11 3.1 75 5.3 0.56* 0.54 0.70
Past use 14 3.9 79 5.5 0.68* 0.77 1.28
Cumulative dosage
< 260 DDDs 15 4.2 75 5.3 0.77 0.78 1.19
≥ 260 DDDs 10 2.8 79 5.5 0.49* 0.52 0.70
Cumulative duration
< 1 year 17 4.8 89 6.2 0.73 0.74 1.14
≥ 1 year 8 2.2 65 4.6 0.47* 0.51 0.68
†: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, and comorbidities.
‡: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, comorbidities, and medications.
OR odds ratios, N number.
*P < 0.05.
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Our current study is the first clinical epidemiological
study to determine whether TZDs have a protective
effect against gastric cancer. The results have demon-
strated a null association between the effect of TZDs
and gastric cancer in diabetic patients in Taiwan.
In our analysis, neither recent use nor past use affected
the association with the overall risk of gastric cancer. How-
ever, increased mean daily dosages of pioglitazone ≥ 260
DDDs (OR = 0.70, P > 0.05) and rosiglitazone ≥ 260
DDDs (OR = 0.79, P > 0.05) were associated with a lower
risk of gastric cancer after adjusting confounders, such as




N = 357 % N = 1,428
Nonuse 323 90.5 1,217
Any use 34 9.5 211
Recent use 10 2.8 25
Past use 24 6.7 186
Cumulative dosage
< 260 DDDs 23 6.4 94
≥ 260 DDDs 11 3.1 117
Cumulative duration
< 1 year 26 7.3 116
≥ 1 year 8 2.2 95
†: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding histo
‡: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding histo
OR odds ratios, N number.
*P < 0.05.history, H. pylori eradication rate, comorbidities, and
medications, which indicated a protective effect from
gastric cancer occurrence with higher TZDs dosages,
but this did not reach statistical significance. A similar
trend was observed when the cumulative duration ≥ 1 year
in pioglitazone (OR = 0.47 P < 0.05) and rosiglitazone
(OR = 0.32 P < 0.05) were associated with a lower risk
of gastric cancer. However, the risk reduction substan-
tially diminished when adjusting for confounding fac-
tors; the statistical significance disappeared. This is not
consistent with previous in vitro studies on TZDs,
which showed antiproliferation and prodifferentiation
effects [19,27,28].ncer risk in a population-based nested case–control
Rosiglitazone
Crude OR †Adjusted OR ‡Adjusted OR
%
85.2 1.00 1.00 1.00
14.8 0.61* 0.75 1.21
1.8 1.51 1.50 1.88
13.0 0.49* 0.62* 0.93
6.6 0.92 1.14 1.69
8.2 0.35* 0.44* 0.79
8.1 0.85 1.04 1.56
6.7 0.32* 0.40* 0.74
ry, Helicobacter pylori eradication rate, and comorbidities.
ry, Helicobacter pylori eradication rate, comorbidities, and medications.
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use and gastric cancer in vitro or in vivo studies
conducted by Leung et al. [27], the growth suppressive
effect of high dosages of PGJ2 (10 uM) and ciglitazone
(20 uM) were accompanied by apoptosis induction with
a modest increase in DNA fragmentation. PPAR-γ li-
gands suppressed both in vitro and in vivo growth of
gastric cancer, and may play a crucial role in cancer
therapy and prevention [18,27]. These results also
showed dose-dependent reduction in COX-2 mRNA ex-
pression after treatment with PPAR-γ ligand. In our
study, we used a cumulative dosage (≥ 260 DDDs) and
duration (≥ 1 year) to evaluate the effect of pioglitazone
or rosiglitazone on the occurrence of gastric cancer in a
clinical epidemiological study but showed a null associ-
ation between TZDs and the occurrence of gastric
cancer.
PPAR-γ is a ligand-dependent transcription factor in-
volved in various processes, including inflammation and
carcinogenesis. Several potential mechanisms have been
proposed and investigated. The basis for therapeutic use
as an anti-diabetic drugs is because the activation of
PPAR-γ leads to improve insulin sensitivity and lower
serum glucose during hyperglycemia. PPAR-γ, in com-
bination with PPAR-γ ligands lowers the effects of
interleukin-1 (IL-1)、IL-6、and tumor necrosis factor-α
(TNF-α) [29]. In an in vitro study, PPAR-γ results in
down-regulation of the expression of proinflammatory
cytokines and inhibition of tumor cell growth [9]. It has
been suggested that PPAR ligands are useful as anti-
inflammatory drugs for inflammatory diseases. The anti-
neoplastic effects are mediated by multiple pathways
including suppression of COX-2, inhibition of the
antiapoptotic B-cell lymphoma-2 (Bcl-2)/Bcl-extra-large
(Bcl-XL) family and cyclin E1, and activation of p53 [27].
This activation of the PPAR ligand can suppress the ac-
tivity of NF-κB [30]. The results of our study are not
consistent with the assumed biological mechanism of
TZDs, although how the mechanism of TZD use may
decrease gastric cancer risk is not well understood or
verified.
Konturek et al. and Slomiany et al. confirmed a direct
link between H. pylori infection gastric cancer patients
and overexpression of PPAR-γ and proinflammatory
cytokines in such infected gastric mucosa [20,31]. Gupta
et al. [32] showed that PPAR-γ ligands significantly at-
tenuated H. pylori–induced apoptosis; this effect was
reversed by co-treatment with a specific PPAR-γ antag-
onist. H. pylori infection is likely to become the first tar-
get in prevention strategies, particularly in high gastric
cancer risk countries [33], such as Taiwan. In our study,
we adjusted the potential confounders, such as the H.
pylori eradication rate, peptic ulcer history, and ulcer
bleeding history, to determine the association of TZDsand the occurrence of gastric cancer. We also controlled
other confounding factors, include comorbidities such as
CAD, CVD, CLD, COPD, CKD, GERD, and EE, and
medications, such as metformin, sulfonylurea, glucosi-
dase inhibitors, meglitinides, DPP-4 inhibitors, insulin,
statins, ARBs, ACE inhibitors, aspirin, NSAIDs, and
COX-2-specific inhibitors to minimize the limitations of
nested case–control studies.
One of the strengths of our study is the use of a com-
puterized database, which is population-based, and is
highly representative. TZDs are available only by pre-
scription. Because TZD-use data were obtained from a
historical database that collected all prescription infor-
mation before the date of gastric cancer diagnosis, the
recall bias for TZDs use was avoided. Second, the pri-
mary exposure of interest was the use of pioglitazone or
rosiglitazone, which entered Taiwan’s market in June
2001 and March 2000, respectively, and is covered
within our patient enrollment in the database.
Caution should be taken in extrapolating our results
to other populations. Certain limitations in our study
exist. First, we did not obtain the H. pylori status and
also had no information on whether the patients ever re-
ceived H. pylori eradication before 1997. H. pylori infec-
tion is associated with gastric cancer development, and
early eradication of H. pylori can reduce the risk of gas-
tric cancer [34]. Therefore, we adjusted confounders,
such as the H. pylori eradication rate, to minimize these
limitations. Second, a lack of patient drug adherence
data was noted in the database for DM patients using
pioglitazone or rosiglitazone; therefore, the drug effects
may have been overestimated. Third, we did not obtain
life-style risk factors, such as smoking, obesity, physical
activity, or family history of gastric cancer, which may
affect the association of DM to gastric cancer. Fourth,
the association of TZDs to gastric cancer might be con-
founded by the severity of DM and the patients’ levels of
glucose control; however, we lacked this data. We could
not examine whether TZDs had a better glucose-
lowering effect compared with non-TZD use. Fifth, we
did not have the socioeconomic status of our patients.
However, confounding by socioeconomic status is min-
imal because the NHI system in Taiwan has comprehen-
sive coverage, and allows patients to visit any clinic or
hospital freely without referral by a general practitioner.
People in Taiwan have few barriers to medical service in
terms of accessibility and cost [35]. Sixth, because of the
relatively small numbers of cases; therefore, well-
designed epidemiologic studies that examine large
computerized health database may provide useful
information to confirm the association of TZDs with
gastric cancer prevention. Because the number of cases
with higher cumulative dosages (≥ 260 DDDs) was rela-
tively small, we were unable to examine the higher
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rence. Moreover, as our average cumulative treatment
duration of TZDs was also relatively shorter, we were
unable to examine the long-term effects of TZDs on gas-
tric cancer occurrence. Seventh, we observed differential
associations between pioglitazone and rosiglitazone with
the occurrence of gastric cancer. Despite numerous
in vitro and animal studies supporting the protective ef-
fects of TZDs, we were unable to identify the exact
underlying physiological pathways that resulted in re-
duced cancer risk. Rosiglitazone has PPAR-γ activity but
pioglitazone has both PPAR-α and PPAR-γ activities.
The medication for cancer protection and inhibition
through dependent and independent pathways may dif-
fer between pioglitazone and rosiglitazone [28,36].
Therefore, we separated pioglitazone and rosiglitazone
to evaluate the risk of occurrence of gastric cancer.
In summary, our study indicates that TZDs cannot
suppress gastric cancer occurrence. This study is
conducted using data from the NHI database, which is
nationwide-based and highly representative. The exact
mechanism must be further elucidated, and the role of
PPAR-γ ligands in chemoprevention and therapy of hu-
man gastric cancer warrants further evaluation. Add-
itional large prospective studies must be conducted to
elucidate this issue.
Conclusions
In conclusion, our results did not provide evidence to
support that TZD derivatives in DM patients reduces
gastric cancer occurrence.
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